Global Multivalent Vaccines Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Multivalent Vaccines Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Multivalent Vaccines by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Multivalent Vaccines by Country/Region, 2017, 2022 & 2028

2.2 Multivalent Vaccines Segment by Type

2.2.1 Conjugate Vaccines

2.2.2 Inactivated and Subunit Vaccines

2.2.3 Live Attenuated Vaccines

2.2.4 Toxoid Vaccines

2.2.5 Recombinant Vaccines

2.3 Multivalent Vaccines Sales by Type

2.3.1 Global Multivalent Vaccines Sales Market Share by Type (2017-2022)

2.3.2 Global Multivalent Vaccines Revenue and Market Share by Type (2017-2022)

2.3.3 Global Multivalent Vaccines Sale Price by Type (2017-2022)

2.4 Multivalent Vaccines Segment by Application

2.4.1 Pediatrics

2.4.2 Adults

2.5 Multivalent Vaccines Sales by Application

2.5.1 Global Multivalent Vaccines Sale Market Share by Application (2017-2022)

2.5.2 Global Multivalent Vaccines Revenue and Market Share by Application (2017-2022)

2.5.3 Global Multivalent Vaccines Sale Price by Application (2017-2022)

3 Global Multivalent Vaccines by Company

3.1 Global Multivalent Vaccines Breakdown Data by Company

3.1.1 Global Multivalent Vaccines Annual Sales by Company (2020-2022)

3.1.2 Global Multivalent Vaccines Sales Market Share by Company (2020-2022)

3.2 Global Multivalent Vaccines Annual Revenue by Company (2020-2022)

3.2.1 Global Multivalent Vaccines Revenue by Company (2020-2022)

3.2.2 Global Multivalent Vaccines Revenue Market Share by Company (2020-2022)

3.3 Global Multivalent Vaccines Sale Price by Company

3.4 Key Manufacturers Multivalent Vaccines Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Multivalent Vaccines Product Location Distribution

3.4.2 Players Multivalent Vaccines Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Multivalent Vaccines by Geographic Region

4.1 World Historic Multivalent Vaccines Market Size by Geographic Region (2017-2022)

4.1.1 Global Multivalent Vaccines Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Multivalent Vaccines Annual Revenue by Geographic Region

4.2 World Historic Multivalent Vaccines Market Size by Country/Region (2017-2022)

4.2.1 Global Multivalent Vaccines Annual Sales by Country/Region (2017-2022)

4.2.2 Global Multivalent Vaccines Annual Revenue by Country/Region

4.3 Americas Multivalent Vaccines Sales Growth

4.4 APAC Multivalent Vaccines Sales Growth

4.5 Europe Multivalent Vaccines Sales Growth

4.6 Middle East & Africa Multivalent Vaccines Sales Growth

5 Americas

5.1 Americas Multivalent Vaccines Sales by Country

5.1.1 Americas Multivalent Vaccines Sales by Country (2017-2022)

5.1.2 Americas Multivalent Vaccines Revenue by Country (2017-2022)

5.2 Americas Multivalent Vaccines Sales by Type

5.3 Americas Multivalent Vaccines Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Multivalent Vaccines Sales by Region

6.1.1 APAC Multivalent Vaccines Sales by Region (2017-2022)

6.1.2 APAC Multivalent Vaccines Revenue by Region (2017-2022)

6.2 APAC Multivalent Vaccines Sales by Type

6.3 APAC Multivalent Vaccines Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Multivalent Vaccines by Country

7.1.1 Europe Multivalent Vaccines Sales by Country (2017-2022)

7.1.2 Europe Multivalent Vaccines Revenue by Country (2017-2022)

7.2 Europe Multivalent Vaccines Sales by Type

7.3 Europe Multivalent Vaccines Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Multivalent Vaccines by Country

8.1.1 Middle East & Africa Multivalent Vaccines Sales by Country (2017-2022)

8.1.2 Middle East & Africa Multivalent Vaccines Revenue by Country (2017-2022)

8.2 Middle East & Africa Multivalent Vaccines Sales by Type

8.3 Middle East & Africa Multivalent Vaccines Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Multivalent Vaccines

10.3 Manufacturing Process Analysis of Multivalent Vaccines

10.4 Industry Chain Structure of Multivalent Vaccines

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Multivalent Vaccines Distributors

11.3 Multivalent Vaccines Customer

12 World Forecast Review for Multivalent Vaccines by Geographic Region

12.1 Global Multivalent Vaccines Market Size Forecast by Region

12.1.1 Global Multivalent Vaccines Forecast by Region (2023-2028)

12.1.2 Global Multivalent Vaccines Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Multivalent Vaccines Forecast by Type

12.7 Global Multivalent Vaccines Forecast by Application

13 Key Players Analysis

13.1 GlaxoSmithKline, plc (U.K.)

13.1.1 GlaxoSmithKline, plc (U.K.) Company Information

13.1.2 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Offered

13.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 GlaxoSmithKline, plc (U.K.) Main Business Overview

13.1.5 GlaxoSmithKline, plc (U.K.) Latest Developments

13.2 Pfizer, Inc (US)

13.2.1 Pfizer, Inc (US) Company Information

13.2.2 Pfizer, Inc (US) Multivalent Vaccines Product Offered

13.2.3 Pfizer, Inc (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Pfizer, Inc (US) Main Business Overview

13.2.5 Pfizer, Inc (US) Latest Developments

13.3 Merck & Co., Inc (US)

13.3.1 Merck & Co., Inc (US) Company Information

13.3.2 Merck & Co., Inc (US) Multivalent Vaccines Product Offered

13.3.3 Merck & Co., Inc (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Merck & Co., Inc (US) Main Business Overview

13.3.5 Merck & Co., Inc (US) Latest Developments

13.4 Sanofi Pasteur SA (France)

13.4.1 Sanofi Pasteur SA (France) Company Information

13.4.2 Sanofi Pasteur SA (France) Multivalent Vaccines Product Offered

13.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Sanofi Pasteur SA (France) Main Business Overview

13.4.5 Sanofi Pasteur SA (France) Latest Developments

13.5 Astellas Pharma Inc. (Japan)

13.5.1 Astellas Pharma Inc. (Japan) Company Information

13.5.2 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Offered

13.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Astellas Pharma Inc. (Japan) Main Business Overview

13.5.5 Astellas Pharma Inc. (Japan) Latest Developments

13.6 CSL Limited (Australia)

13.6.1 CSL Limited (Australia) Company Information

13.6.2 CSL Limited (Australia) Multivalent Vaccines Product Offered

13.6.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 CSL Limited (Australia) Main Business Overview

13.6.5 CSL Limited (Australia) Latest Developments

13.7 Emergent BioSolutions, Inc (US)

13.7.1 Emergent BioSolutions, Inc (US) Company Information

13.7.2 Emergent BioSolutions, Inc (US) Multivalent Vaccines Product Offered

13.7.3 Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Emergent BioSolutions, Inc (US) Main Business Overview

13.7.5 Emergent BioSolutions, Inc (US) Latest Developments

13.8 Johnson & Johnson (US)

13.8.1 Johnson & Johnson (US) Company Information

13.8.2 Johnson & Johnson (US) Multivalent Vaccines Product Offered

13.8.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Johnson & Johnson (US) Main Business Overview

13.8.5 Johnson & Johnson (US) Latest Developments

13.9 MedImmune, LLC (US)

13.9.1 MedImmune, LLC (US) Company Information

13.9.2 MedImmune, LLC (US) Multivalent Vaccines Product Offered

13.9.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 MedImmune, LLC (US) Main Business Overview

13.9.5 MedImmune, LLC (US) Latest Developments

13.10 Serum Institute of India Pvt. Ltd. (India)

13.10.1 Serum Institute of India Pvt. Ltd. (India) Company Information

13.10.2 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Offered

13.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Serum Institute of India Pvt. Ltd. (India) Main Business Overview

13.10.5 Serum Institute of India Pvt. Ltd. (India) Latest Developments

13.11 Bavarian Nordic (Denmark)

13.11.1 Bavarian Nordic (Denmark) Company Information

13.11.2 Bavarian Nordic (Denmark) Multivalent Vaccines Product Offered

13.11.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Bavarian Nordic (Denmark) Main Business Overview

13.11.5 Bavarian Nordic (Denmark) Latest Developments

13.12 Mitsubishi Tanabe Pharma Corporation (Japan)

13.12.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Information

13.12.2 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Offered

13.12.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Mitsubishi Tanabe Pharma Corporation (Japan) Main Business Overview

13.12.5 Mitsubishi Tanabe Pharma Corporation (Japan) Latest Developments

13.13 Daiichi Sankyo (Japan)

13.13.1 Daiichi Sankyo (Japan) Company Information

13.13.2 Daiichi Sankyo (Japan) Multivalent Vaccines Product Offered

13.13.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Daiichi Sankyo (Japan) Main Business Overview

13.13.5 Daiichi Sankyo (Japan) Latest Developments

13.14 Protein Sciences Corporation (US)

13.14.1 Protein Sciences Corporation (US) Company Information

13.14.2 Protein Sciences Corporation (US) Multivalent Vaccines Product Offered

13.14.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Protein Sciences Corporation (US) Main Business Overview

13.14.5 Protein Sciences Corporation (US) Latest Developments

13.15 Panacea Biotec (India)

13.15.1 Panacea Biotec (India) Company Information

13.15.2 Panacea Biotec (India) Multivalent Vaccines Product Offered

13.15.3 Panacea Biotec (India) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Panacea Biotec (India) Main Business Overview

13.15.5 Panacea Biotec (India) Latest Developments

14 Research Findings and Conclusion

Table 1. Multivalent Vaccines Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Multivalent Vaccines Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Conjugate Vaccines

Table 4. Major Players of Inactivated and Subunit Vaccines

Table 5. Major Players of Live Attenuated Vaccines

Table 6. Major Players of Toxoid Vaccines

Table 7. Major Players of Recombinant Vaccines

Table 8. Global Multivalent Vaccines Sales by Type (2017-2022) & (K Pcs)

Table 9. Global Multivalent Vaccines Sales Market Share by Type (2017-2022)

Table 10. Global Multivalent Vaccines Revenue by Type (2017-2022) & ($ million)

Table 11. Global Multivalent Vaccines Revenue Market Share by Type (2017-2022)

Table 12. Global Multivalent Vaccines Sale Price by Type (2017-2022) & (USD/Pcs)

Table 13. Global Multivalent Vaccines Sales by Application (2017-2022) & (K Pcs)

Table 14. Global Multivalent Vaccines Sales Market Share by Application (2017-2022)

Table 15. Global Multivalent Vaccines Revenue by Application (2017-2022)

Table 16. Global Multivalent Vaccines Revenue Market Share by Application (2017-2022)

Table 17. Global Multivalent Vaccines Sale Price by Application (2017-2022) & (USD/Pcs)

Table 18. Global Multivalent Vaccines Sales by Company (2020-2022) & (K Pcs)

Table 19. Global Multivalent Vaccines Sales Market Share by Company (2020-2022)

Table 20. Global Multivalent Vaccines Revenue by Company (2020-2022) ($ Millions)

Table 21. Global Multivalent Vaccines Revenue Market Share by Company (2020-2022)

Table 22. Global Multivalent Vaccines Sale Price by Company (2020-2022) & (USD/Pcs)

Table 23. Key Manufacturers Multivalent Vaccines Producing Area Distribution and Sales Area

Table 24. Players Multivalent Vaccines Products Offered

Table 25. Multivalent Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 26. New Products and Potential Entrants

Table 27. Mergers & Acquisitions, Expansion

Table 28. Global Multivalent Vaccines Sales by Geographic Region (2017-2022) & (K Pcs)

Table 29. Global Multivalent Vaccines Sales Market Share Geographic Region (2017-2022)

Table 30. Global Multivalent Vaccines Revenue by Geographic Region (2017-2022) & ($ millions)

Table 31. Global Multivalent Vaccines Revenue Market Share by Geographic Region (2017-2022)

Table 32. Global Multivalent Vaccines Sales by Country/Region (2017-2022) & (K Pcs)

Table 33. Global Multivalent Vaccines Sales Market Share by Country/Region (2017-2022)

Table 34. Global Multivalent Vaccines Revenue by Country/Region (2017-2022) & ($ millions)

Table 35. Global Multivalent Vaccines Revenue Market Share by Country/Region (2017-2022)

Table 36. Americas Multivalent Vaccines Sales by Country (2017-2022) & (K Pcs)

Table 37. Americas Multivalent Vaccines Sales Market Share by Country (2017-2022)

Table 38. Americas Multivalent Vaccines Revenue by Country (2017-2022) & ($ Millions)

Table 39. Americas Multivalent Vaccines Revenue Market Share by Country (2017-2022)

Table 40. Americas Multivalent Vaccines Sales by Type (2017-2022) & (K Pcs)

Table 41. Americas Multivalent Vaccines Sales Market Share by Type (2017-2022)

Table 42. Americas Multivalent Vaccines Sales by Application (2017-2022) & (K Pcs)

Table 43. Americas Multivalent Vaccines Sales Market Share by Application (2017-2022)

Table 44. APAC Multivalent Vaccines Sales by Region (2017-2022) & (K Pcs)

Table 45. APAC Multivalent Vaccines Sales Market Share by Region (2017-2022)

Table 46. APAC Multivalent Vaccines Revenue by Region (2017-2022) & ($ Millions)

Table 47. APAC Multivalent Vaccines Revenue Market Share by Region (2017-2022)

Table 48. APAC Multivalent Vaccines Sales by Type (2017-2022) & (K Pcs)

Table 49. APAC Multivalent Vaccines Sales Market Share by Type (2017-2022)

Table 50. APAC Multivalent Vaccines Sales by Application (2017-2022) & (K Pcs)

Table 51. APAC Multivalent Vaccines Sales Market Share by Application (2017-2022)

Table 52. Europe Multivalent Vaccines Sales by Country (2017-2022) & (K Pcs)

Table 53. Europe Multivalent Vaccines Sales Market Share by Country (2017-2022)

Table 54. Europe Multivalent Vaccines Revenue by Country (2017-2022) & ($ Millions)

Table 55. Europe Multivalent Vaccines Revenue Market Share by Country (2017-2022)

Table 56. Europe Multivalent Vaccines Sales by Type (2017-2022) & (K Pcs)

Table 57. Europe Multivalent Vaccines Sales Market Share by Type (2017-2022)

Table 58. Europe Multivalent Vaccines Sales by Application (2017-2022) & (K Pcs)

Table 59. Europe Multivalent Vaccines Sales Market Share by Application (2017-2022)

Table 60. Middle East & Africa Multivalent Vaccines Sales by Country (2017-2022) & (K Pcs)

Table 61. Middle East & Africa Multivalent Vaccines Sales Market Share by Country (2017-2022)

Table 62. Middle East & Africa Multivalent Vaccines Revenue by Country (2017-2022) & ($ Millions)

Table 63. Middle East & Africa Multivalent Vaccines Revenue Market Share by Country (2017-2022)

Table 64. Middle East & Africa Multivalent Vaccines Sales by Type (2017-2022) & (K Pcs)

Table 65. Middle East & Africa Multivalent Vaccines Sales Market Share by Type (2017-2022)

Table 66. Middle East & Africa Multivalent Vaccines Sales by Application (2017-2022) & (K Pcs)

Table 67. Middle East & Africa Multivalent Vaccines Sales Market Share by Application (2017-2022)

Table 68. Key Market Drivers & Growth Opportunities of Multivalent Vaccines

Table 69. Key Market Challenges & Risks of Multivalent Vaccines

Table 70. Key Industry Trends of Multivalent Vaccines

Table 71. Multivalent Vaccines Raw Material

Table 72. Key Suppliers of Raw Materials

Table 73. Multivalent Vaccines Distributors List

Table 74. Multivalent Vaccines Customer List

Table 75. Global Multivalent Vaccines Sales Forecast by Region (2023-2028) & (K Pcs)

Table 76. Global Multivalent Vaccines Sales Market Forecast by Region

Table 77. Global Multivalent Vaccines Revenue Forecast by Region (2023-2028) & ($ millions)

Table 78. Global Multivalent Vaccines Revenue Market Share Forecast by Region (2023-2028)

Table 79. Americas Multivalent Vaccines Sales Forecast by Country (2023-2028) & (K Pcs)

Table 80. Americas Multivalent Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)

Table 81. APAC Multivalent Vaccines Sales Forecast by Region (2023-2028) & (K Pcs)

Table 82. APAC Multivalent Vaccines Revenue Forecast by Region (2023-2028) & ($ millions)

Table 83. Europe Multivalent Vaccines Sales Forecast by Country (2023-2028) & (K Pcs)

Table 84. Europe Multivalent Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)

Table 85. Middle East & Africa Multivalent Vaccines Sales Forecast by Country (2023-2028) & (K Pcs)

Table 86. Middle East & Africa Multivalent Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)

Table 87. Global Multivalent Vaccines Sales Forecast by Type (2023-2028) & (K Pcs)

Table 88. Global Multivalent Vaccines Sales Market Share Forecast by Type (2023-2028)

Table 89. Global Multivalent Vaccines Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 90. Global Multivalent Vaccines Revenue Market Share Forecast by Type (2023-2028)

Table 91. Global Multivalent Vaccines Sales Forecast by Application (2023-2028) & (K Pcs)

Table 92. Global Multivalent Vaccines Sales Market Share Forecast by Application (2023-2028)

Table 93. Global Multivalent Vaccines Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 94. Global Multivalent Vaccines Revenue Market Share Forecast by Application (2023-2028)

Table 95. GlaxoSmithKline, plc (U.K.) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 96. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Offered

Table 97. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 98. GlaxoSmithKline, plc (U.K.) Main Business

Table 99. GlaxoSmithKline, plc (U.K.) Latest Developments

Table 100. Pfizer, Inc (US) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 101. Pfizer, Inc (US) Multivalent Vaccines Product Offered

Table 102. Pfizer, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 103. Pfizer, Inc (US) Main Business

Table 104. Pfizer, Inc (US) Latest Developments

Table 105. Merck & Co., Inc (US) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 106. Merck & Co., Inc (US) Multivalent Vaccines Product Offered

Table 107. Merck & Co., Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 108. Merck & Co., Inc (US) Main Business

Table 109. Merck & Co., Inc (US) Latest Developments

Table 110. Sanofi Pasteur SA (France) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 111. Sanofi Pasteur SA (France) Multivalent Vaccines Product Offered

Table 112. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 113. Sanofi Pasteur SA (France) Main Business

Table 114. Sanofi Pasteur SA (France) Latest Developments

Table 115. Astellas Pharma Inc. (Japan) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 116. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Offered

Table 117. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 118. Astellas Pharma Inc. (Japan) Main Business

Table 119. Astellas Pharma Inc. (Japan) Latest Developments

Table 120. CSL Limited (Australia) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 121. CSL Limited (Australia) Multivalent Vaccines Product Offered

Table 122. CSL Limited (Australia) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 123. CSL Limited (Australia) Main Business

Table 124. CSL Limited (Australia) Latest Developments

Table 125. Emergent BioSolutions, Inc (US) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 126. Emergent BioSolutions, Inc (US) Multivalent Vaccines Product Offered

Table 127. Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 128. Emergent BioSolutions, Inc (US) Main Business

Table 129. Emergent BioSolutions, Inc (US) Latest Developments

Table 130. Johnson & Johnson (US) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 131. Johnson & Johnson (US) Multivalent Vaccines Product Offered

Table 132. Johnson & Johnson (US) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 133. Johnson & Johnson (US) Main Business

Table 134. Johnson & Johnson (US) Latest Developments

Table 135. MedImmune, LLC (US) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 136. MedImmune, LLC (US) Multivalent Vaccines Product Offered

Table 137. MedImmune, LLC (US) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 138. MedImmune, LLC (US) Main Business

Table 139. MedImmune, LLC (US) Latest Developments

Table 140. Serum Institute of India Pvt. Ltd. (India) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 141. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Offered

Table 142. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 143. Serum Institute of India Pvt. Ltd. (India) Main Business

Table 144. Serum Institute of India Pvt. Ltd. (India) Latest Developments

Table 145. Bavarian Nordic (Denmark) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 146. Bavarian Nordic (Denmark) Multivalent Vaccines Product Offered

Table 147. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 148. Bavarian Nordic (Denmark) Main Business

Table 149. Bavarian Nordic (Denmark) Latest Developments

Table 150. Mitsubishi Tanabe Pharma Corporation (Japan) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 151. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Offered

Table 152. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 153. Mitsubishi Tanabe Pharma Corporation (Japan) Main Business

Table 154. Mitsubishi Tanabe Pharma Corporation (Japan) Latest Developments

Table 155. Daiichi Sankyo (Japan) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 156. Daiichi Sankyo (Japan) Multivalent Vaccines Product Offered

Table 157. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 158. Daiichi Sankyo (Japan) Main Business

Table 159. Daiichi Sankyo (Japan) Latest Developments

Table 160. Protein Sciences Corporation (US) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 161. Protein Sciences Corporation (US) Multivalent Vaccines Product Offered

Table 162. Protein Sciences Corporation (US) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 163. Protein Sciences Corporation (US) Main Business

Table 164. Protein Sciences Corporation (US) Latest Developments

Table 165. Panacea Biotec (India) Basic Information, Multivalent Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 166. Panacea Biotec (India) Multivalent Vaccines Product Offered

Table 167. Panacea Biotec (India) Multivalent Vaccines Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 168. Panacea Biotec (India) Main Business

Table 169. Panacea Biotec (India) Latest Developments

List of Figures

Figure 1. Picture of Multivalent Vaccines

Figure 2. Multivalent Vaccines Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Multivalent Vaccines Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Multivalent Vaccines Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Multivalent Vaccines Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Conjugate Vaccines

Figure 10. Product Picture of Inactivated and Subunit Vaccines

Figure 11. Product Picture of Live Attenuated Vaccines

Figure 12. Product Picture of Toxoid Vaccines

Figure 13. Product Picture of Recombinant Vaccines

Figure 14. Global Multivalent Vaccines Sales Market Share by Type in 2021

Figure 15. Global Multivalent Vaccines Revenue Market Share by Type (2017-2022)

Figure 16. Multivalent Vaccines Consumed in Pediatrics

Figure 17. Global Multivalent Vaccines Market: Pediatrics (2017-2022) & (K Pcs)

Figure 18. Multivalent Vaccines Consumed in Adults

Figure 19. Global Multivalent Vaccines Market: Adults (2017-2022) & (K Pcs)

Figure 20. Global Multivalent Vaccines Sales Market Share by Application (2017-2022)

Figure 21. Global Multivalent Vaccines Revenue Market Share by Application in 2021

Figure 22. Multivalent Vaccines Revenue Market by Company in 2021 ($ Million)

Figure 23. Global Multivalent Vaccines Revenue Market Share by Company in 2021

Figure 24. Global Multivalent Vaccines Sales Market Share by Geographic Region (2017-2022)

Figure 25. Global Multivalent Vaccines Revenue Market Share by Geographic Region in 2021

Figure 26. Global Multivalent Vaccines Sales Market Share by Region (2017-2022)

Figure 27. Global Multivalent Vaccines Revenue Market Share by Country/Region in 2021

Figure 28. Americas Multivalent Vaccines Sales 2017-2022 (K Pcs)

Figure 29. Americas Multivalent Vaccines Revenue 2017-2022 ($ Millions)

Figure 30. APAC Multivalent Vaccines Sales 2017-2022 (K Pcs)

Figure 31. APAC Multivalent Vaccines Revenue 2017-2022 ($ Millions)

Figure 32. Europe Multivalent Vaccines Sales 2017-2022 (K Pcs)

Figure 33. Europe Multivalent Vaccines Revenue 2017-2022 ($ Millions)

Figure 34. Middle East & Africa Multivalent Vaccines Sales 2017-2022 (K Pcs)

Figure 35. Middle East & Africa Multivalent Vaccines Revenue 2017-2022 ($ Millions)

Figure 36. Americas Multivalent Vaccines Sales Market Share by Country in 2021

Figure 37. Americas Multivalent Vaccines Revenue Market Share by Country in 2021

Figure 38. United States Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 39. Canada Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 40. Mexico Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 41. Brazil Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 42. APAC Multivalent Vaccines Sales Market Share by Region in 2021

Figure 43. APAC Multivalent Vaccines Revenue Market Share by Regions in 2021

Figure 44. China Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 45. Japan Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 46. South Korea Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 47. Southeast Asia Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 48. India Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 49. Australia Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 50. Europe Multivalent Vaccines Sales Market Share by Country in 2021

Figure 51. Europe Multivalent Vaccines Revenue Market Share by Country in 2021

Figure 52. Germany Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 53. France Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 54. UK Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 55. Italy Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 56. Russia Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 57. Middle East & Africa Multivalent Vaccines Sales Market Share by Country in 2021

Figure 58. Middle East & Africa Multivalent Vaccines Revenue Market Share by Country in 2021

Figure 59. Egypt Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 60. South Africa Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 61. Israel Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 62. Turkey Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 63. GCC Country Multivalent Vaccines Revenue Growth 2017-2022 ($ Millions)

Figure 64. Manufacturing Cost Structure Analysis of Multivalent Vaccines in 2021

Figure 65. Manufacturing Process Analysis of Multivalent Vaccines

Figure 66. Industry Chain Structure of Multivalent Vaccines

Figure 67. Channels of Distribution

Figure 68. Distributors Profiles